Relmada Therapeutics Inc (RLMD NASDAQ) stock market data APIs
$2.6201
0.23(8.8%)
as of November 6, 2025
Try our APIs with
free plan!
Relmada Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prev. Close
2.6201
Open
2.8482
High
2.8813
Low
2.4157
52 wk Range
0.2404-3.425
Market Cap
83 311 K
Shares Outstanding
33 192 K
EPS
0
Beta
0.833
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Relmada Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Relmada Therapeutics Inc data using free add-ons & libraries
Get Relmada Therapeutics Inc Fundamental Data
Relmada Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -161 247 824
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Relmada Therapeutics Inc News
New
Relmada Therapeutics Leads These 3 Promising Penny Stocks
On November 4, 2025, major U.S. stock indexes closed sharply lower, with tech stocks leading the decline and Bitcoin experiencing a notable drop. In such volatile market conditions, investors often se...
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expecte...
Promising Penny Stocks To Watch In October 2025
As the U.S. stock market navigates the complexities of a government shutdown and fluctuating employment figures, major indices like the Dow Jones have managed to shake off early declines, reflecting r...
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Relmada Therapeutics, Inc. is one of them. Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
